Pacira BioSciences, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $192.4M | $177.4M | $196.9M | $179.5M | $181.1M | $168.9M | $187.3M | $168.6M |
| Cost of Revenue | $44.2M | $36.4M | $40.3M | $34.3M | $40.9M | $34.3M | $39.9M | $38.9M |
| Gross Profit | $148.2M | $141.0M | $156.6M | $145.2M | $140.2M | $134.6M | $147.4M | $129.7M |
| Gross Margin | 77.0% | 79.5% | 79.5% | 80.9% | 77.4% | 79.7% | 78.7% | 76.9% |
| Operating Expenses | ||||||||
| Research & Development | $30.2M | $28.1M | $37.8M | $26.0M | $28.2M | $25.3M | $23.9M | $19.1M |
| SG&A Expense | $91.8M | $93.9M | $101.6M | $91.8M | $88.6M | $86.8M | $79.6M | $74.3M |
| Operating Income | $4.3M | $6.9M | $2.3M | $6.4M | $8.5M | $2.0M | $24.7M | $-139.5M |
| Operating Margin | 2.2% | 3.9% | 1.2% | 3.5% | 4.7% | 1.2% | 13.2% | -82.8% |
| Interest Expense | $3.6M | $3.7M | $3.9M | $4.3M | $4.7M | $4.6M | $4.7M | $4.7M |
| Pretax Income | $2.6M | $5.0M | $571.0K | $9.5M | $-1.9M | $8.7M | $25.5M | $-138.9M |
| Income Tax Expense | $-2.1M | $2.1M | $-1.1M | $4.1M | $2.9M | $3.9M | $9.5M | $4.6M |
| Net Income | $4.7M | $2.9M | $1.6M | $5.4M | $-4.8M | $4.8M | $16.0M | $-143.5M |
| Net Margin | 2.4% | 1.6% | 0.8% | 3.0% | -2.7% | 2.8% | 8.6% | -85.1% |
| EPS (Basic) | $0.12 | $0.07 | $0.05 | $0.12 | $-0.11 | $0.10 | $0.36 | $-3.11 |
| EPS (Diluted) | $0.12 | $0.07 | $0.05 | $0.12 | $-0.11 | $0.10 | $0.38 | $-3.11 |
| Shares Outstanding (Basic) | 39.5M | 40.5M | 44.6M | 44.0M | 45.5M | 46.3M | 46.2M | 46.1M |
| Shares Outstanding (Diluted) | 40.3M | 40.9M | 45.0M | 44.5M | 45.5M | 46.5M | 46.2M | 46.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |